<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04294927</url>
  </required_header>
  <id_info>
    <org_study_id>NL 70691.091.19</org_study_id>
    <nct_id>NCT04294927</nct_id>
  </id_info>
  <brief_title>TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention</brief_title>
  <acronym>TUBA-WISP-II</acronym>
  <official_title>TUBectomy With Delayed Oophorectomy as Alternative for Risk-reducing Salpingo-oophorectomy in High Risk Women to Assess the Safety of Prevention: TUBA-WISP II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Nijmegen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Nijmegen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the project is to evaluate the risk-reducing salpingectomy with delayed
      oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women
      with respect to ovarian cancer incidence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In BRCA1/2 gene mutation carriers, a risk-reducing salpingo-oophorectomy (RRSO) is
      recommended around the age of 40. This recommendation is based on a 10-40% life-time risk of
      ovarian cancer in this population and disappointing results of ovarian cancer surveillance
      for early detection. Moreover, the mortality rate of ovarian cancer is high. Effects of RRSO
      are a decrease in ovarian cancer risk (80-96%) on one hand and immediate onset of menopause
      and non-cancer related morbidity on the other hand. The fifty percent breast cancer risk
      reduction after RRSO has become disputable in the last years. Based on multiple studies
      showing that most high-grade serous ovarian cancers develop at the distal end of the
      Fallopian tube, an innovative strategy for RRSO has been developed for this study proposal:
      risk-reducing salpingectomy (RRS) with delayed risk-reducing oophorectomy (RRO). However, the
      safety of this strategy has not been proven yet. Before implementing this innovative strategy
      as standard care we need to investigate the long term effects on ovarian cancer incidence.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">February 17, 2040</completion_date>
  <primary_completion_date type="Anticipated">February 17, 2040</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>High grade serous (ovarian) cancer incidence</measure>
    <time_frame>Until the age of 45 for BRCA1 and 50 for BRCA2 germline mutation carriers</time_frame>
    <description>High grade serous (ovarian) cancer incidence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of (pre)malignant findings in tubes/ovaries</measure>
    <time_frame>6 weeks after each surgery</time_frame>
    <description>Incidence of (pre)malignant findings in tubes/ovaries at risk-reducing salpingectomy, oophorectomy and salpingo-oophorectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-operative morbidity and mortality</measure>
    <time_frame>6 weeks after each surgery</time_frame>
    <description>Peri-operative morbidity and mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pelvic cancer (other than ovarian cancer)</measure>
    <time_frame>Up to the age of 70</time_frame>
    <description>Incidence of pelvic cancer (other than ovarian cancer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of breast cancer</measure>
    <time_frame>Up to the age of 70</time_frame>
    <description>Incidence of breast cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uptake of risk reducing oophorectomy</measure>
    <time_frame>Up to the age of 70</time_frame>
    <description>Uptake of risk reducing oophorectomy after risk reducing salpingectomy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>High grade serous (ovarian) cancer incidence at the age of 70</measure>
    <time_frame>Up to the age of 70</time_frame>
    <description>Exploratory outcome measure</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>BRCA1 Gene Mutation</condition>
  <condition>BRCA2 Gene Mutation</condition>
  <condition>RAD51C Gene Mutation</condition>
  <condition>RAD51D Gene Mutation</condition>
  <condition>BRIP1 Gene Mutation</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Risk-reducing salpingectomy with delayed oophorectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risk-reducing salpingectomy after the completion of childbearing with delayed oophorectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risk-reducing salpingo-oophorectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Risk-reducing salpingo-oophorectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Risk-reducing salpingectomy with delayed oophorectomy</intervention_name>
    <description>BRCA1: RRS at age 25-40 and RRO at a maximum age of 45 (advised between 35 and 45).
BRCA2: RRS at age 25-45 and RRO at a maximum age of 50 (advised between age 40 and 50).
BRIP1, RAD51C, RAD51D: RRS at age 25-50 and RRO at a maximum age of 55 (advised between 45 and 55)</description>
    <arm_group_label>Risk-reducing salpingectomy with delayed oophorectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Risk-reducing salpingo-oophorectomy</intervention_name>
    <description>BRCA1 at a maximum age of 40 (advised between age 35 and 40)
BRCA2 at a maximum age of 45 (advised between age 40 and 45)
BRIP1, RAD51C, RAD51D: at a maximum age of 50 (advised between 45 and 50)</description>
    <arm_group_label>Risk-reducing salpingo-oophorectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with a class 5 (definitely pathogenic) BRCA1, BRCA2, RAD51C, RAD51D or BRIP1
             germline mutation in one of the participating centers.

          -  Age at inclusion;

               -  BRCA1: 25-40 years

               -  BRCA2: 25-45 years

               -  RAD51C, RAD51D, BRIP1: 25-50 years

          -  Childbearing completed

          -  Presence of at least one fallopian tube

          -  Participants may have a personal history of non-ovarian malignancy

          -  Informed consent must be obtained and documented according to national and local
             regulatory requirements and the local rules followed in the institution.

        Exclusion Criteria:

          -  Postmenopausal status (natural menopause or due to treatment)

          -  Wish for second stage RRO within two years after RRS

          -  Legally incapable

          -  Prior bilateral salpingectomy

          -  A personal history of ovarian, fallopian tube or peritoneal cancer

          -  Current diagnosis or treatment for malignant disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne A. de Hullu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen H. Lu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosella P.M.G. Hermens, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth M. Swisher, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanne A. de Hullu, MD, PhD</last_name>
    <phone>+31 (0) 24 36 16683</phone>
    <email>Joanne.deHullu@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen H. Lu, MD, PhD</last_name>
    <phone>(713) 745-8902</phone>
    <email>khlu@mdanderson.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne A. de Hullu, MD, PhD</last_name>
      <phone>+31 (0) 24 36 16683</phone>
      <email>Joanne.deHullu@radboudumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jurgen M.J. Piek, MD, PhD</last_name>
      <email>jurgen.piek@catharinaziekenhuis.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 1, 2020</study_first_submitted>
  <study_first_submitted_qc>March 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Nijmegen</investigator_affiliation>
    <investigator_full_name>Joanne A. de Hullu, MD, PhD</investigator_full_name>
    <investigator_title>Dr. J.A. de Hullu, MD, PhD</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

